ADAM8/17 Emerges as a Promising Drug Target in Intrahepatic Cholangiocarcinoma

Intrahepatic cholangiocarcinoma, an aggressive cancer arising from the bile ducts within the liver, remains one of the most difficult gastrointestinal malignancies to treat. Surgical resection offers the only realistic chance of cure, yet most patients are diagnosed too late for surgery, and the standard chemotherapy regimen of gemcitabine plus cisplatin provides only modest benefit. Against this grim backdrop, a new study published in the Journal of Cancer Research and Clinical Oncology points to a pair of enzymes that may finally offer a meaningful molecular foothold: ADAM8 and ADAM17, members of the A Disintegrin and Metalloproteinase family, which the researchers identify as both a driver of tumor development and a viable drug target.

The research team, led by Kaisi Yang and corresponding authors Yingshi Zhang and Qingchun Zhao, working across Shenyang Pharmaceutical University, the General Hospital of Northern Theater Command, and Wannan Medical University Affiliated Tongling People’s Hospital, assembled a multi-layered case for ADAM8/17’s involvement in this cancer. Their investigation began with bioinformatic mining of publicly available gene expression datasets, which revealed that ADAM8 is highly and specifically overexpressed in intrahepatic cholangiocarcinoma compared with surrounding tissue and other tumor types. This pattern of selective elevation is exactly what drug developers look for in a target: a molecule that is abundant in the disease but dispensable elsewhere, minimizing the risk of collateral toxicity.

Correlation alone, however, has long been a trap in cancer genomics. Many genes are merely passengers that ride along with tumor progression without causing it. To address this, the team turned to Mendelian randomization, a statistical technique that uses naturally occurring genetic variants as instruments to test whether an exposure, in this case ADAM8/17 expression, plausibly causes a disease outcome rather than simply accompanying it. By combining two-sample Mendelian randomization analyses with a meta-analysis across independent datasets, the researchers found that genetically influenced ADAM8/17 activity and its downstream Notch signaling pathway were closely linked to the occurrence and development of intrahepatic cholangiocarcinoma. This causal framing substantially strengthens the argument that these proteases are active participants in tumor biology rather than bystanders.

ADAM8 and ADAM17 are membrane-anchored enzymes known as sheddases, meaning they cleave the extracellular portions of other membrane proteins and release them into the surrounding environment. Among their substrates are signaling molecules and receptors that fuel inflammation, angiogenesis, and cell proliferation. The Notch pathway, which the study implicates as a downstream mediator, is a highly conserved cell-to-cell communication system that governs cell fate decisions; when dysregulated, it can promote tumor growth, epithelial-mesenchymal transition, and resistance to therapy. The idea that blocking ADAM8/17 could simultaneously dampen Notch-driven malignancy gives the target additional mechanistic appeal.

Identifying a target is only half the battle; the harder task is finding a molecule that disables it. Through molecular docking simulations, the team screened for small compounds capable of binding the catalytic machinery of ADAM8/17 and landed on a candidate they designated NY-2. To confirm that the compound genuinely engages its target inside cells rather than merely fitting a computational model, the researchers employed a cellular thermal shift assay. This technique exploits a simple physical principle: proteins stabilized by a bound ligand resist heat-induced denaturation. The assay demonstrated that NY-2 shifts the thermal stability of ADAM8/17 in cells, providing direct biochemical evidence of target engagement, a step that many candidate drugs fail to clear.

With target engagement established, the team moved into functional testing using an impressive battery of models. Patient-derived organoids, miniature three-dimensional tumor cultures grown from actual patient tissue, retain much of the cellular diversity and drug responsiveness of the original tumors, making them a far more faithful testing ground than conventional cell lines. In these organoids, alongside standard MTT proliferation assays, Transwell migration experiments, apoptosis measurements, and cell cycle analyses, NY-2 consistently suppressed the hallmarks of cancer progression: cells stopped dividing, migration was curtailed, and programmed cell death increased. The compound also arrested cells at specific checkpoints in the cell cycle, further choking off tumor expansion.

The mechanistic payoff came from western blotting experiments that mapped exactly which signaling cascades NY-2 disrupts. The results showed that the compound acts through two converging arms. The first is the Notch1–HIF1α–VEGFA axis, a chain in which Notch1 signaling stabilizes the hypoxia-inducible factor HIF1α, which in turn drives vascular endothelial growth factor A production, fueling the blood vessel growth that tumors need to enlarge and spread. The second is the Integrinα5–TGFβ–Smad pathway, in which the adhesion molecule integrin alpha-5 feeds into transforming growth factor beta signaling and its intracellular Smad effectors, a circuit intimately tied to epithelial-mesenchymal transition, the process by which cancer cells acquire invasive and metastatic properties. By suppressing both routes simultaneously, NY-2 attacks the tumor’s growth supply line and its invasion machinery at once.

The clinical significance of these findings is sharpened by the study’s prognostic data, which showed that high ADAM8/17 expression is associated with poor outcomes in patients with intrahepatic cholangiocarcinoma. This dual role, as both a biomarker of aggressive disease and a pharmacologically actionable target, is rare and valuable. It suggests a future in which ADAM8/17 expression levels could help stratify patients most likely to benefit from a targeted inhibitor, moving treatment away from one-size-fits-all chemotherapy toward precision oncology for a cancer that desperately needs it.

The authors are careful to frame this as a foundation rather than a finished therapy. Their stated next steps include gene editing experiments to confirm the target’s necessity and orthotopic liver tumor models, in which tumors are implanted directly into the liver to recreate the organ environment more faithfully than subcutaneous models. Such studies will be essential before any compound derived from NY-2 can approach clinical trials, and the history of cancer drug development is littered with promising preclinical targets that failed to translate. Nevertheless, the breadth of evidence here, spanning population genetics, structural biology, thermal proteomics, and patient-derived models, gives the ADAM8/17 hypothesis unusual depth.

For patients with intrahepatic cholangiocarcinoma, whose five-year survival remains dismal and whose treatment options have barely expanded in decades, the identification of a druggable, causally implicated target with a validated small-molecule inhibitor is a genuinely encouraging signal. The work also exemplifies a modern drug discovery paradigm: computational biology to nominate a target, Mendelian randomization to establish causality, docking and thermal shift assays to validate engagement, and organoids to demonstrate efficacy. If subsequent in vivo studies confirm what this research suggests, ADAM8/17 inhibition could become one of the most closely watched strategies in biliary tract cancer therapeutics.

Subject of Research: The role of ADAM8/17 proteases and the Notch1/Integrinα5 pathway in the development and targeted treatment of intrahepatic cholangiocarcinoma

Article Title: Novel drug target ADAM8/17 is associated with the occurrence of intrahepatic cholangiocarcinoma via Notch1/Integrinα5 pathway

Article References: Yang, K., Han, L., Song, X., Wang, C., Wang, Z., Zhu, Z., Xu, T., Mao, M., Xu, Z., Zhang, Y., & Zhao, Q. (2026). Novel drug target ADAM8/17 is associated with the occurrence of intrahepatic cholangiocarcinoma via Notch1/Integrinα5 pathway. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-026-06616-4

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06616-4

Keywords: intrahepatic cholangiocarcinoma, ADAM8, ADAM17, NY-2 inhibitor, Notch1 signaling, Integrinα5, HIF1α, VEGFA, TGFβ-Smad pathway, Mendelian randomization, patient-derived organoids, targeted therapy